CJC/IPA Protocol vs Ipamorelin
Well Studied vs Well Studied
synergistic Mechanism-based · 55% CJC/IPA Protocol and Ipamorelin amplify GH release through complementary mechanisms (GHRH primes, GHRP triggers). This is a well-established synergistic combination — expect significantly greater GH output than either alone.
Molecular Data
CJC/IPA Protocol Ipamorelin
Weight N/A 711.85 Da
Half-life — ~2 hours
Chain N/A 5 amino acids
Type Peptide combination (GHRH analog + GHS) Growth hormone secretagogue
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
CJC/IPA Protocol Ipamorelin
Status Well Studied Well Studied
References 4 studies 5 studies
Latest June 2024 October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.